Pfizer pulls sickle cell treatment Oxbryta off global markets

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

The decision is a stunning blow for a drug that was approved in 2019, heralded as a new way to treat the inherited blood disorder. Pfizer acquired the maker of Oxbryta, a biotech company called Global Blood Therapeutics, in 2022 for $5.4 billion.

In a statement, Pfizer said the decision to voluntarily withdraw Oxbryta was made based on data showing the drug’s benefit no longer outweighed the risks. Data suggested the drug might increase the risk of pain crises and “fatal events.”

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Ever-growing global diabetes burden exacerbated by large-scale inequity

Despite increased awareness and ongoing multinational efforts, diabetes is pervasive, exponentially growing in prevalence, and outpacing most diseases globally, according to a new Series published

July 5, 2023

Salk researchers uncover molecular mechanisms of HIV drug resistance

Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) becomes resistant

July 22, 2023

Almost 75% of Hawaii Wildfire Survey Participants Have Respiratory Issues

A University of Hawaii study examining the health effects of last year’s deadly wildfires on Maui found that up to 74% of participants may have

May 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.